Development of Multiplex Polymerase Chain Reaction (PCR)-Based MSA Assay for Bladder Cancer Detection.
bladder cancer
loss of heterozygosity
microsatellite instability
triplet MSA assay
Journal
International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791
Informations de publication
Date de publication:
04 Sep 2023
04 Sep 2023
Historique:
received:
23
07
2023
revised:
18
08
2023
accepted:
28
08
2023
medline:
11
9
2023
pubmed:
9
9
2023
entrez:
9
9
2023
Statut:
epublish
Résumé
Several studies have shown that microsatellite changes can be profiled in the urine to detect bladder cancer. Microsatellite analysis (MSA) of bladder cancer detection requires a comprehensive analysis of up to 15-20 markers based on amplifying and interpreting many individual MSA markers, which can be technically challenging. To develop fast, efficient, standardized, and less costly MSA to detect bladder cancer, we developed three multiplex polymerase chain reaction (PCR) based MSA assays, all of which were analyzed by a genetic analyzer. First, we selected 16 MSA markers based on nine publications. We developed MSA assays based on triplet or three-tube-based multiplex PCR (Triplet MSA assay) using samples from Johns Hopkins University (JHU Sample, first set of samples). In the second set of samples (samples from six cancer patients and fourteen healthy individuals), our Triplet Assay with 15 MSA markers correctly predicted all 6/6 cancer samples to be cancerous and 14/14 healthy samples to be healthy. Although we could improve our report with more clinical information from patient samples and an increased number of cancer patients, our overall results suggest that our Triplet MSA Assay combined with a genetic analyzer is a potentially time- and cost-effective genetic assay for bladder cancer detection and has potential use as a dependable assay in patient care.
Identifiants
pubmed: 37686456
pii: ijms241713651
doi: 10.3390/ijms241713651
pmc: PMC10488090
pii:
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Pyung-Ya Foundation
ID : This research was funded by the Cancer Research Grant from Pyung-Ya Foundation (grant number PY-1; to C.S.M.) and Translational Research Grant from HJM Foundation (grant number HJM-TR1; to C.S.M. and D.M.).
Références
Science. 1993 May 7;260(5109):816-9
pubmed: 8484122
Annu Rev Pathol. 2009;4:251-85
pubmed: 18840072
Jpn J Clin Oncol. 2006 Mar;36(3):172-5
pubmed: 16520358
Int J Cancer. 2001 Nov 20;95(6):364-9
pubmed: 11668518
J Surg Res. 2010 Jun 1;161(1):89-94
pubmed: 19500801
Eur Urol. 2003 Apr;43(4):369-73
pubmed: 12667717
Carcinogenesis. 2008 Apr;29(4):673-80
pubmed: 17942460
Nat Med. 1997 Jun;3(6):621-4
pubmed: 9176487
Eur Urol. 2011 Jun;59(6):997-1008
pubmed: 21458150
BJU Int. 2009 Jul;104(1):41-7
pubmed: 19500328
Int J Cancer. 2002 Sep 20;101(3):293-7
pubmed: 12209982
Magy Onkol. 2009 Dec;53(4):385-9
pubmed: 20071311
Int J Cancer. 1998 Dec 18;79(6):629-33
pubmed: 9842973
Urology. 2003 Jan;61(1):109-18; discussion 118
pubmed: 12559279
J Clin Oncol. 2006 Dec 10;24(35):5552-64
pubmed: 17158541
Pharmacoeconomics. 2003;21(18):1315-30
pubmed: 14750899
Eur Urol. 2017 Mar;71(3):447-461
pubmed: 27324428
Urol Oncol. 2010 Jul-Aug;28(4):389-400
pubmed: 20610277
Oncogene. 2001 Feb 8;20(6):686-91
pubmed: 11314002
World J Urol. 2008 Feb;26(1):45-50
pubmed: 18180926
Clin Cancer Res. 2003 Jan;9(1):257-63
pubmed: 12538478
CA Cancer J Clin. 2009 Jul-Aug;59(4):225-49
pubmed: 19474385
Arch Toxicol. 2015 Jun;89(6):899-921
pubmed: 25701956
Cancer Epidemiol Biomarkers Prev. 2009 Jun;18(6):1798-806
pubmed: 19454613
Science. 1996 Feb 2;271(5249):659-62
pubmed: 8571131
J Clin Pathol. 2006 Sep;59(9):984-7
pubmed: 16935973
Dis Markers. 2004;20(4-5):237-50
pubmed: 15528789
J Clin Oncol. 2010 Jul 10;28(20):3380-7
pubmed: 20516444
BJU Int. 2008 Jan;101(1):26-9
pubmed: 17850364
Int J Cancer. 2000 Mar 1;85(5):614-7
pubmed: 10699938
Urology. 2007 Sep;70(3):449-53
pubmed: 17688921
Cancer. 2009 Sep 15;115(18):4096-103
pubmed: 19536899
Urology. 2010 Aug;76(2):513.e13-8
pubmed: 20605198
Urol Res. 1998;26(4):223-33
pubmed: 9759995
J Urol. 2007 Dec;178(6):2314-30
pubmed: 17993339
Stat Med. 1992 Oct-Nov;11(14-15):1825-39
pubmed: 1480876
World J Gastroenterol. 2014 Apr 14;20(14):3927-37
pubmed: 24744582
Eur Urol. 2009 Mar;55(3):659-67
pubmed: 18501499
J Natl Cancer Inst. 2001 Jan 3;93(1):45-50
pubmed: 11136841
Int J Cancer. 2007 Jul 15;121(2):329-38
pubmed: 17373664
Urology. 2006 May;67(5):950-4
pubmed: 16698355
Adv Clin Path. 2000 Jan;4(1):19-24
pubmed: 10936895
World J Urol. 2008 Feb;26(1):13-8
pubmed: 18030473
Cancer. 2006 Feb 25;108(1):60-5
pubmed: 16411183
Urology. 1999 Sep;54(3):561
pubmed: 10754137
Am J Surg Pathol. 2010 Mar;34(3):371-6
pubmed: 20139762
Cancer Lett. 2001 Oct 22;172(1):55-8
pubmed: 11595129
J Urol. 2001 Jan;165(1):249-52
pubmed: 11125419
Cancer Res. 2003 Sep 15;63(18):5723-6
pubmed: 14522891
Exp Biol Med (Maywood). 2019 Mar;244(3):227-240
pubmed: 30760030
World J Gastroenterol. 2012 Jun 14;18(22):2745-55
pubmed: 22719182
J Clin Oncol. 2006 Dec 10;24(35):5519-27
pubmed: 17158537
Oncogene. 2001 Aug 16;20(36):5005-14
pubmed: 11526485
Cancer Res. 2000 Aug 15;60(16):4617-22
pubmed: 10969815
Eur Urol. 2007 Dec;52(6):1601-9
pubmed: 17919807
Int J Mol Sci. 2021 Nov 28;22(23):
pubmed: 34884669
Int J Cancer. 1997 Dec 19;74(6):625-9
pubmed: 9421360
J Mol Med (Berl). 1996 Aug;74(8):441-5
pubmed: 8872857
Cancer. 2001 Aug 15;92(4):768-75
pubmed: 11550146
Nat Rev Genet. 2004 Jun;5(6):435-45
pubmed: 15153996
Cancer Treat Rev. 2016 Dec;51:19-26
pubmed: 27838401
Electrophoresis. 1999 Feb;20(2):280-2
pubmed: 10197434
Anal Quant Cytol Histol. 2001 Dec;23(6):381-7
pubmed: 11777271
J Surg Res. 2007 Dec;143(2):422-7
pubmed: 17612565
Nature. 1993 Jun 10;363(6429):558-61
pubmed: 8505985
Science. 1993 May 7;260(5109):812-6
pubmed: 8484121
Ann Clin Lab Sci. 2006 Winter;36(1):31-8
pubmed: 16501234
Eur Urol. 2005 Jun;47(6):736-48
pubmed: 15925067